Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04035889 (ClinicalTrials.gov)	September 23, 2019	25/7/2019	Melatonin for Sleep in MS	A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)	Multiple Sclerosis	Dietary Supplement: Melatonin;Dietary Supplement: Placebo	University of California, San Francisco	NULL	Completed	20 Years	70 Years	All	30	N/A	United States
2	NCT03498131 (ClinicalTrials.gov)	May 9, 2018	6/4/2018	Melatonin in Patients With Multiple Sclerosis (MS).	Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)	Relapsing Remitting Multiple Sclerosis	Drug: 3 mg Melatonin;Drug: 5 mg Melatonin	Providence Health & Services	NULL	Active, not recruiting	18 Years	65 Years	All	30	Early Phase 1	United States
3	EUCTR2012-004183-21-GB (EUCTR)	25/01/2013	14/12/2012	Melatonin for Nocturia in patients with Multiple Sclerosis	A randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension study - Melatonin for Nocturia in MS	Nocturia; Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Circadin Product Name: Circadin Product Code: N/A INN or Proposed INN: Circadin ( INN= Melatonin)	North Bristol NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	80	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
4	NCT02463318 (ClinicalTrials.gov)	September 2012	2/6/2015	The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects		Multiple Sclerosis;Oxidative Stress	Drug: Melatonin;Other: Hydrogen peroxide	Tehran University of Medical Sciences	NULL	Completed	20 Years	40 Years	Female	34	N/A	Iran, Islamic Republic of
5	NCT01718678 (ClinicalTrials.gov)	May 2012	28/10/2012	Effect of Melatonin on Multiple Sclerosis Related Fatigue	Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis	Fatigue	Drug: Melatonin;Drug: Placebo	Isfahan University of Medical Sciences	NULL	Completed	18 Years	55 Years	Both	44	Phase 2	Iran, Islamic Republic of
6	NCT01279876 (ClinicalTrials.gov)	October 2010	18/1/2011	Melatonin in Relapsing-Remitting Multiple Sclerosis Patients	Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients	Multiple Sclerosis, Relapsing-Remitting	Drug: Melatonin	Tehran University of Medical Sciences	NULL	Completed	20 Years	45 Years	Both	25	Phase 2	Iran, Islamic Republic of

先頭へ